Blood Reviews
Volume 20, Issue 5 , Pages 235-244 , September 2006

The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma

References 

  1. Fisher RI, LeBlanc M, Press OW, et al. New Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma. J Clin Oncol 2005.
  2. Johnson PWM, Rohatiner AZS, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol. 1995;13:140–147
  3. Freedman AS, Neuberg D, Mauch P, et al. Long-term follow-Up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma [In Process Citation]. Blood. 1999;94:3325–3333
  4. Hunault-Berger M, Ifrah N, Solal-Celigny P. Intensive therapies in follicular non-Hodgkin lymphomas. Blood. 2002;100:1141–1152
  5. Colombat P, Donadio D, Fouillard L, et al. Value of autologous bone marrow transplantation in follicular lymphoma: a France Autogreffe retrospective study of 42 patients. Bone Marrow Transplant. 1994;13:157–162
  6. Bierman PJ, Vose JM, Anderson JR, et al. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin’s lymphoma. J Clin Oncol. 1997;15:445–450
  7. Apostolidis J, Gupta RK, Grenzelias D, et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol. 2000;18:527–536
  8. Voso MT, Martin S, Hohaus S, et al. Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT). Bone Marrow Transplant. 2000;25:957–964
  9. Bastion Y, Brice P, Haioun C, et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood. 1995;86:3257–3262
  10. Weaver CH, Schwartzberg L, Rhinehart S, et al. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin’s lymphoma. Bone Marrow Transplant. 1998;21:383–389
  11. Berglund A, Enblad G, Carlson K, Glimelius B, Hagberg H. Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma. Eur J Haematol. 2000;65:17–22
  12. Brice P, Simon D, Bouabdallah R, et al. High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. Ann Oncol. 2000;11:1585–1590
  13. Verdonck LF, Dekker AW, Lokhorst HM, Petersen EJ, Nieuwenhuis HK. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low grade non Hodgkin’s lymhoma. Blood. 1997;90:4201–4205
  14. Cervantes F, Shu XO, McGlave PB, et al. Autologous bone marrow transplantation for non-transformed low- grade non-Hodgkin’s lymphoma. Bone Marrow Transplant. 1995;16:387–392
  15. Cao TM, Horning S, Negrin RS, et al. High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience. Biol Blood Marrow Transplant. 2001;7:294–301
  16. van Besien K, Loberiza FR, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003;102:3521–3529
  17. Molina A, Nademanee A, O’Donnell M. Long-term follow-up and analysis of prognostic factors after high dose therapy and peripheral blood stem cell autografting in 58 patients with a history of low grade lymphoma [abstract]. Blood. 1999;94(Suppl 1):171a
  18. Seyfarth B, Kuse R, Sonnen R, et al. Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant?. Ann Hematol. 2001;80:398–405
  19. Stein RS, Greer JP, Goodman S, et al. High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin. Bone Marrow Transplant. 1999;23:227–233
  20. Pham RA, Gooley TA, Keeney GE, et al. The impact of histologic grade on the outcome of high-dose therapy and autologous transplantation for follicular lymphoma [abstract]. Blood. 2005;106:679
  21. Van BK, Loberiza FR, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003;102:3521–3529
  22. Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21:3918–3927
  23. Freedman AS, Gribben JG, Neuberg D. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood. 1996;88:2780–2786
  24. Horning SJ, Negrin RS, Hoppe RT, et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood. 2001;97:404–409
  25. Corradini P, Ladetto M, Zallio F, et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol. 2004;22:1460–1468
  26. Rohatiner AZ, Gregory WM, Peterson B, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol. 2005;23:2215–2223
  27. Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood. 2004;104:2667–2674
  28. Deconinck E, Foussard C, Milpied N, et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood. 2005;105:3817–3823
  29. Lenz G, Dreyling M, Unterhalt M, Hiddemann W. In Reply:Should we Transplant patients with indolent lymphoma. J Clin Oncol. 2005;23:6264–6266
  30. Sebban C, Belanger C, Brousse N, et al. Comparison of CHVP + Interferon with CHOP Followed by Autologous Stem Cell Transplantation with a TBI Conditioning Regimen in Untreated Patients with High Tumor Burden Follicular Lymphoma: Results of the Randomized GELF94 Trial (G.E.L.A. Study Group) [abstract]. Blood. 2003;102:#354
  31. Nabhan C. Should we transplant indolent lymphoma?. J Clin Oncol. 2005;23:6263–6264
  32. Hiddemann W, Kneba M, Dreyling M, et al. Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone - results of a prospective randomized study of the german low grade lymphoma study group (GLSG). Blood 2005.
  33. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417–1423
  34. Metayer C, Curtis RE, Vose J, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood. 2003;101:2015–2023
  35. Bhatia S, Ramsay NK, Steinbuch M, et al. Malignant neoplasms following bone marrow transplantation. Blood. 1996;87:3633–3639
  36. Andre M, Henry-Amar M, Blaise D, et al. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin’s disease. Blood. 1998;92:1933–1940
  37. Abruzzese E, Radford JE, Miller JS, et al. Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation. Blood. 1999;94:1814–1819
  38. Lillington DM, Micallef IN, Carpenter E, et al. Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin’s lymphoma. J Clin Oncol. 2001;19:2472–2481
  39. Williams CD, Goldstone AH, Pearce RM, et al. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin’s lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol. 1996;14:2454–2464
  40. Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000;96:2934–2942
  41. Vose JM, Bierman PJ, Enke C, et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:461–467
  42. Nademanee A, Forman S, Molina A, et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood. 2005;106:2896–2902
  43. Winter JN, Inwards D, Erwin W, et al. Zevalin dose-escalation followed by high-dose beam and autotransplant in cd20+ relapsed or refractory non-hodgkin lymphoma (NHL) [abstract]. Biol Blood Marrow Transplant. 2004;10(Suppl 1):28
  44. Fung H, Forman SJ, Nademanee A, et al. A new preparative regimen for older patients with aggressive CD 20 positive B-cell lymphoma utilizing standard dose yttrium-90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) combined with high-dose BEAM followed by autologous hematopoietic cell transplantation (AHCT): targeted intensification without increased transplant-related toxicity [abstract]. Blood. 2003;102:248a
  45. Gopal AK, Gooley TA, Maloney DG, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood. 2003;102:2351–2357
  46. Devizzi L, Seregni E, Guidetti A, et al. High dose myeloablative zevalin radioimmunotherapy with tandem stem-cell autografting has minimal toxicity and full feasibility in an outpatient setting [abstract]. Blood. 2005;106:2737a
  47. Gribben JG, Freedman AS, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma [see comments]. New England. Journal of Medicine 1991;325:1525–1533.
  48. Gribben JG, Nadler LM. Detection of minimal residual disease in patients with lymphomas using the polymerase chain reaction. [Review]. Important Advances in Oncology. 1994;117–129
  49. Bierman PJ, Sweetenham JW, Loberiza FM, et al. Syngeneic Hematopoietic Stem Cell Transplantation for Non-Hodgkin’s Lymphoma: A Comparison with Allogeneic and Autologous Transplantation. J Clin Oncol. 2003;3744–3753
  50. Ladetto M, Corradini P, Vallet S, et al. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood. 2002;100:1559–1565
  51. Fouillard L, Laporte JP, Labopin M, et al. Autologous stem-cell transplantation for non-Hodgkin’s lymphomas: the role of graft purging and radiotherapy posttransplantation–results of a retrospective analysis on 120 patients autografted in a single institution. J Clin Oncol. 1998;16:2803–2816
  52. Flinn IW, O’Donnell PV, Goodrich A, et al. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2000;6:628–632
  53. Lemieux B, Tartas S, Traulle C, et al. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2004;33:921–923
  54. Lazzarino M, Arcaini L, Bernasconi P, et al. A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br J Haematol. 2002;116:229–235
  55. Galimberti S, Guerrini F, Morabito F, et al. Quantitative molecular evaluation in autotransplant programs for follicular lymphoma: efficacy of in vivo purging by Rituximab. Bone Marrow Transplant. 2003;32:57–63
  56. Hoerr AL, Gao F, Hidalgo J, et al. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin’s lymphoma. J Clin Oncol. 2004;22:4561–4566
  57. Belhadj K, Hicheri Y, Pautas C. Benefit of the adjunction of rituximab in salvage regimen before autologous stem cell transplantation in follicular lymphoma at relapse. A single institution study [abstract]. Blood. 2005;106:2075a
  58. Ladetto M, Ricca I, Benedetti F, et al. Rituximab supplemented high dose sequential chemotherapy has superior response rate and event free survival compared to R-CHOP in poor risk follicular lymphoma at diagnosis [abstract]. Blood. 2005;106:675a
  59. Burns LJ, Weisdorf DJ, DeFor TE, et al. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplant. 2003;32:177–186
  60. van Besien K, Mehra R, Wadehra N, et al. Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2004;10:386–394
  61. Nagler A, Ackerstein A, Or R, Naparstek E, Slavin S. Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation. Blood. 1997;89:3951–3959
  62. Brugger W, Hirsch J, Grunebach F, et al. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol. 2004;15:1691–1698
  63. Khouri I, Saliba R, Hosing C, et al. Autologous stem cell vs non-myeloablative allogeneic transplantation after high-dose rituximab containing conditioning regimens for relapsed chemosensitive lymphoma [abstract]. Blood. 2005;106:48a
  64. Smith SM, Grinblatt D, Gajewski T, et al. Prospective Study of Immunomodulation with GM-CSF, IL-2, and Rituximab Following Autologous Stem Cell Transplant (SCT) in Patients with Relapsed Lymphomas [abstract]. Blood. 2004;104:#918
  65. van Besien K, Sobocinski K, Rowlings P, et al. Allogeneic bone marrow transplantation for low grade lymphoma. Blood. 1998;92:1832–1836
  66. van Besien K, Carreras J, Zhang M-J, et al. Reduced Intensity vs Myeloablative Conditioning for HLA-Matched Sibling Transplantation in Follicular Lymphoma [abstract]. Blood. 2005;106:656a
  67. Khouri IF, Saliba RM, Giralt SA, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001;98:3595–3599
  68. Mandigers CM, Verdonck LF, Meijerink JP, et al. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant. 2003;32:1159–1163
  69. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003;31:667–678
  70. Robinson SP, Mackinnon S, Goldstone A, et al. Higher than expected transplant-related mortality and relapse following non-myeloablative stem cell transplantation for lymphoma adversely affects survival [abstract]. Blood. 2000;96(Suppl 1):#2380
  71. Faulkner RD, Craddock C, Byrne JL, et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood. 2004;103:428–434
  72. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–2919
  73. Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood. 2004;104:961–968
  74. Artz AS. Comorbidity and beyond: pre-transplant clinical assessment. Bone Marrow Transplant. 2005;36:473–474
  75. Thomson KJ, Peggs KS, Smith P, et al. Improved outcome following reduced intensity allogeneic transplantation in Hodgkin’s lymphoma relapsing post-autologous transplantation [abstract]. Blood. 2005;106:657a
  76. Kahl C, Storer B, Mielcarek M, et al. Relapse risk after nonmyeloablative hematopoietic cell transplantation for malignant diseases [abstract]. Blood. 2005;106:703a
  77. Mandigers CM, Raemaekers JM, Schattenberg AV, et al. Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor-risk relapsed low-grade non-Hodgkin’s lymphoma. Br J Haematol. 1998;100:198–206
  78. Verdonck LF. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin’s lymphoma: updated results of the Utrecht experience. Leuk Lymphoma. 1999;34:129–136
  79. Toze CL, Shepherd JD, Connors JM, et al. Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia. Bone Marrow Transplant. 2000;25:605–612
  80. Forrest D, Matheson K, Couban S, Nevill T, Fernandez L. High dose therapy and allogeneic hematopietic stem cell transplantation for progressive follicular lymphoma [abstract]. Blood. 2001;98(suppl. 1):408a
  81. Morris E, Thomson K, Craddock C, et al. Outcome Following Alemtuzumab (CAMPATH-1H) -Containing Reduced Intensity Allogeneic Transplant Regimen for Relapsed and Refractory Non-Hodgkin’s Lymphoma (NHL). Blood 2004.
  82. Maris MB, Sandmaier BM, Storer B, et al. Allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning for relapsed or refractory follicular lymphoma [abstract]. Blood. 2005;106:1130a

PII: S0268-960X(06)00003-8

doi: 10.1016/j.blre.2006.01.001

Blood Reviews
Volume 20, Issue 5 , Pages 235-244 , September 2006

Article Tools

* Image Usage & Resolution